BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

The country of origin effect is often observed in expensive or status-related products, such as wine and cars. Vaccines, on ...

Demand for the jab through the NHS and privately in pharmacies has remained steady since the end of the pandemic ...

Turkish scientists say that Pfizer's COVID-19 vaccine can increase the risk of eye damage, causing vision loss. A new study ...

The results revealed that taking both doses of Pfizer's COVID-19 vaccine led to fewer endothelial cells in the eye and ...

COVID hospitalizations rise as pediatric cases surge 03:16. Pfizer will have a COVID-19 vaccine that specifically targets the Omicron variant ready by March, the pharmaceutical company's chief ...

Eight months after authorizing the Pfizer-BioNTech COVID-19 vaccine for emergency use in the USA, the Food and Drug Administration issued its full stamp of approval.. Now that the companies ...

Potential COVID-19 vaccine vials from Pfizer, Oct. 31, 2020. Dado Ruvic/Reuters, FILE Early data revealed Monday that Pfizer's COVID-19 vaccine candidate could be up to 90% effective .

Kids ages 5 to 11 will soon be able to get Pfizer's low-dose COVID vaccine. CDC director Rochelle Walensky agreed with a unanimous decision of a team of advisers that the benefits outweigh the risks.

Pfizer and BioNTech said Tuesday they have submitted Covid-19 vaccine data on children ages 5 to 11 to the FDA for initial review, but are not yet seeking emergency use authorization.